ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Executive SummaryThe market for pharmaceutical therapies aimed at disorders of the central nervous system (CNS) is substantial. Diseases such as depression and anxiety, schizophrenia and psychosis, epilepsy, Alzheimer's disease, Parkinson's disease and stroke are serious and often life-threatening conditions for which there are clear and pressing therapeutic needs. The US market for CNS drugs was over $US22 billion in 2001 and it is forecast to increase to about $US32 billion in 2006 – an approximate 40% increase in value.Most CNS markets are well over $US1 billion in sales in the US. Depression is the single largest market segment with 39% of sales in 2001, followed by schizophrenia at 18%. Segments predicted to increase in relative importance by 2006 include schizophrenia, Alzheimer's disease and attention deficit/hyperactivity disorder (ADHD). Relative to 2001, depression will decline the most in importance.Pfizer, Eli Lilly, GlaxoSmithKline, Bristol Myers-SquibbandJohnson & Johnsonare the current market leaders. In 2001, Pfizer was dominant in both sales ($US4.4 billion) and market share (19.5%). In the next few years, many of the players will not show much overall dynamism. Overall,AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Lilly,Novartisand Pfizer are the companies currently best positioned in the CNS market – based on current sales, commitment to CNS R&D, pipeline depth, patent risk to existing business, deal activity, sales and marketing strength and potential product launches.Companies showing the greatest dollar growth through 2006 will be AstraZeneca, GlaxoSmithKline and Pfizer. GlaxoSmithKline, Johnson & Johnson, Lilly and Novartis show the best balance of sales volume and sales growth. Companies with declining businesses includeRocheandPharmacia. Roche will suffer from generic competition and an aging product line.Pharmaciawill lose substantial revenues from the transfer of Ambien (zolpidem) toSanofi-Synthelabo; however, the impact of this was diminished by the April 2003 takeover of the company by Pfizer.

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Executive SummaryCardiology is the largest category of healthcare expense in the US – surpassing cancer and infectious diseases by a large margin. The market for prescription cardiology therapies is expected to average a healthy 8.5% growth through 2007, reaching sales of $US43.5 billion. Acute coronary syndrome (ACS), arrhythmia, atherosclerosis and angina segment growths will exceed the average category growth. Atherosclerosis and hypertension will increase in importance, growing the 85% of cardiology sales.Twelve major companies account for 28.5% of the overall cardiology pipeline. This suggests that as smaller companies' programs mature, more often than not, they will partner with these major firms for market launch. Atherosclerosis and ACS have the greatest number of programs in development. When percent distribution is examined, it is clear that CHF and arrhythmia are also considered relatively more important by the major firms. Surprisingly, there is a not a strong correlation between cardiology sales volume across the seven indications reviewed and distribution of pipeline programs across the same indications. Given the size of the individual markets, it would be expected that the atherosclerosis and hypertension pipelines would constitute the bulk of the development effort. On the other hand, one would expect that the restenosis and arrhythmia pipelines would represent less than 7% of the pipeline count when in fact they account for 13% of the major firms' effort and 14% of the total effort. This apparent anomaly suggests that, at present, Big Pharma does not see the possibility for significant R&D breakthrough in the biggest markets and so companies have started to explore niche opportunities throughout cardiology.Pfizer,Bristol-Myers Squibband, to a lesser degree,Aventisare clearly the best-positioned companies in the cardiology market.Merck & Co.'s strong 2001 cardiology sales position is at risk by virtue of its patent expiration situation coupled with a poor clinical pipeline and it is expected that the company's long-term performance in cardiology will erode. Pfizer andPharmaciawill enjoy the broadest success experiencing sales growth in six of the seven indications reviewed; together, the merged company will be a formidable presence in the cardiology market. Bristol-Myers Squibb is considered to be the only company that is clearly in a ‘building a business’ mode;AstraZenecais expected to transition from ‘riding winners’ to the ‘building a business’ quadrant; Merck,Schering-Plough,AbbottandRocheare in a ‘milking’ posture with both their current portfolio and limited product development.

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Executive SummaryThe sequencing of the human genome has generated a drug discovery process that is based on sequence analysis and hypothesis-driven (inductive) prediction of gene function. This approach, which we terminductive genomics, is currently dominating the efforts of the pharmaceutical industry to identify new drug targets. According to recent studies, this sequence-driven discovery process is paradoxically increasing the average cost of drug development, thus falling short of the promise of the Human Genome Project to simplify the creation of much needed novel therapeutics. In the early stages of discovery, the flurry of new gene sequences makes it difficult to pick and prioritize the most promising product candidates for product development, as with existing technologies important decisions have to be based on circumstantial evidence that does not strongly predict therapeutic potential. This is because the physiological function of a potential target cannot be predicted by gene sequence analysis andin vitrotechnologies alone.In contrast,deductive genomics, or large-scale forward genetics, bridges the gap between sequence and function by providing a function-drivenin vivoscreen of a highly orthologous mammalian model genome for medically relevant physiological functions and drug targets. This approach allows drug discovery to move beyond the focus on sequence-driven identification of new members of classical druggable protein families towards the biology-driven identification of innovative targets and biological pathways.

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Executive SummaryWhile good progress has been seen in the development of drugs and other therapeutic approaches to cancer, advances in diagnostic tools have not kept pace and continue to lag. Many current diagnostic tools provide only limited information and often show poor correlation with disease progression and response to therapy. Notably, the available tools tend to provide ‘lagging’ rather than ‘leading’ indicators of therapeutic efficacy and the course of disease.These problems are not just limited to the clinical situation but also impact on trials for new cancer drugs, because the same diagnostic tools are often employed to assess a drug's potential effectiveness, particularly in early-stage clinical studies. What is needed is improved diagnostic technologies to allow clinicians and researchers alike to make better-informed decisions.One company trying to fill the void is Immunicon Corporation. The company has developed and integrated several patented, state-ofthe-art technologies for the separation, isolation, manipulation and analysis of cells – in particular, rare cells. This “federation” of technologies is based on CellTracks Technology that is incorporated in the CellTracks AutoPrep System, CellSearch reagents and the CellTracks Analyzer.Immunicon's primary market for its technology is the cancer diagnostics market. Currently the company is completing its first pivotal clinical trial for breast cancer monitoring that will lead to an FDA submission for its first cancer diagnostic product. Other potential cellular analysis applications include isolation of fetal cells from maternal blood and microbiology/virology testing such as HIV-infected CD4 lymphocytes.

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1061-2270    

出版商:ADIS    

年代:2003

数据来源: ADIS